As the Authority identified a risk of adverse effects due to interactions with medicinal products, it is necessary to warn persons using cholesterol-lowering medicines, to avoid concomitant use of foods containing monacolins from red yeast rice. The Authority noted that the profile of adverse effects to red yeast rice was similar to that of lovastatin, therefore, it is appropriate to warn persons to seek medical advice if they experience any health problems. Furthermore, as the Authority could not evaluate the safe use of monacolins in certain vulnerable groups of consumers because of the lack of data, and as therefore, there is still the possibility of harmful effects on health associated with the use of monacolins from red yeast rice, it is appropriate to advise against the use of foods containing monacolins from red yeast rice for pregnant or lactating women, persons aged over 70 years, children and adolescents. Considering the above, it is necessary to provide for appropriate labelling requirements for all foods containing monacolins from red yeast rice.
Recital 17, Regulation (EU) 2022/860
In forcesince 1 Jun 2022